Program
roxadustat
Also written as “Roxadustat”, “FG-4592” and “ASP1517”.
Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Myelodysplastic Syndromes · Renal Insufficiency, led by 3 companies.
Drug pageRoxadustat: every studyAll 63 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharmaits history only | 221 open or running | phase 3since Jun 25, 2013 | Sep 15, 2009 | Oct 30, 2027phase 3 · NCT05970172 |
| Kyntra Bioits history only | 221 open or running | phase 4since Aug 8, 2019 | Sep 25, 2008 | Sep 2030phase 3 · NCT07722988 |
| AstraZeneca | 30 open or running | phase 4since Dec 3, 2020 | Jun 24, 2014 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 24, 2014First studies: 2 phase 3 studies in AnemiaFirst studyNCT02174731, NCT02174627
- Dec 3, 2020Phase 4 study in Renal Insufficiency, ChronicNCT04655027 · 25 enrolled · China
TargetBeta
“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daprodustatrule | GlaxoSmithKline | phase 3 | 33 |
Studies
All 3 AstraZeneca leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04655027Renal Insufficiency, Chronic · China | 4 | Completed | Oct 12, 2021 | 25 |
| NCT02174731Anemia · United States, Australia, Bulgaria and more | 3 | Completed | Sep 26, 2018 | 2,133 |
| NCT02174627Anemia · United States, Argentina, Brazil and more | 3 | Completed | Oct 4, 2018 | 2,781 |
How it is read
Names in the registry
- “Roxadustat”, 25 entries
- “FG-4592”, 9 entries
- “roxadustat”, 8 entries
- “ASP1517”, 5 entries
Conditions, from the studies’ own filings
- Anemia, 25 studies
- Renal Insufficiency, Chronic, 7 studies
- Kidney Failure, Chronic, 4 studies
- Myelodysplastic Syndromes, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.